Symbiotec Pharmalab544889Quarterly results
Board approves Sept 2026 quarter and half-year results; limited review conclusion unmodified
Board meeting on November 05, 2026 approved the unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2026.
By ScoutQuest · · 2 min read
| Line item | Latest | Year ago | YoY | Prev qtr | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 2,799.28 | 1,955.15 | +43.2% | 2,181.50 | +28.3% |
| Total income | 2,800.40 | 1,956.75 | +43.1% | 2,184.88 | +28.2% |
| Profit before tax | 640.44 | 334.70 | +91.3% | 175.32 | +265% |
| Profit after tax | 517.18 | 192.18 | +169% | 140.61 | +268% |
| Total comprehensive income | 524.05 | 192.78 | +172% | 141.27 | +271% |
| Basic EPS | 8.20 | 3.45 | +138% | 2.24 | +266% |
- Total income YoY growth
- +43.1%
- Period
- September 30,2026 (Unaudited)
Auditor's review
Conclusion: Unmodified
Notes to the results
- IPO of 1,77,86,442 equity shares at Rs. 988 per share completed in the quarter; fresh issue of 15,21,261 shares aggregating Rs. 1,500.00 million; listed on NSE and BSE on September 1, 2026.
- Net IPO proceeds of Rs. 1,420.25 million (net of IPO expenses Rs. 79.75 million); Rs. 1,420.00 million utilised and Rs. 0.25 million unutilised as at September 30, 2026.
- Figures for quarter and half year ended September 30, 2025 compiled by management and not subjected to review or audit by statutory auditors.
- Exceptional item for year ended March 31, 2026 relates to impact of new wage code on gratuity and leave encashment, an expense of Rs. 89.93 million.
Symbiotec Pharmalab's board met on Thursday, November 05, 2026, and approved the unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2026. The statutory auditors, S R B C & Co LLP, issued limited review reports on both sets of results.
What the board approved
- Unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2026, reviewed by the Audit Committee and then approved by the board.
- The auditors' limited review reports on the results were placed on record.
Consolidated results (the statement is drawn up in Rs. in million)
- 'Revenue from operations' was 2,799.28 for the quarter ended September 30, 2026, against 1,955.15 for the quarter ended September 30, 2025.
- 'Net Profit for the period' was 517.18 for the quarter and 657.79 for the half year.
- The prior-year comparatives were not audited or reviewed by the auditors; the company states they were compiled by management using consistent accounting policies.
Auditor's review conclusion
- A limited review is not a full audit. It gives moderate assurance and is substantially narrower in scope than an audit, so it does not express an audit opinion.
- The conclusion on both the standalone and consolidated statements is unmodified: nothing came to the auditors' attention that causes them to believe the statements contain a material misstatement.
- The consolidated statement includes subsidiaries whose interim financial information was not reviewed by any auditor. Management has told the auditors this information is not material to the Group, and the auditors' conclusion is not modified on this account.
IPO and where the money went
- The company completed its initial public offering during the quarter and its equity shares were listed on NSE and BSE on September 1, 2026, at an issue price of Rs. 988 per equity share of face value Rs. 2.
- The offering combined a fresh issue of equity shares aggregating to Rs. 1,500.00 million with an offer for sale by selling shareholders.
- Net proceeds received by the company were Rs. 1,420.25 million, net of IPO expenses.
- Up to September 30, 2026, Rs. 1,125.00 million of the net proceeds had been used for prepayment and/or repayment, in full or in part, of certain outstanding borrowings, with the balance used for general corporate purposes.
Other points from the notes
- The Group's business is a single segment: manufacturing and selling of pharmaceutical products and services.
- In the quarter, the company allotted fresh shares, which increased its paid-up equity share capital; the change is reflected in the balance sheet and cash flow statement.
The update is a routine quarterly disclosure. The points a retail reader can check are the auditor's unmodified review conclusion on both statements, the consolidated revenue and profit lines for the quarter and half year, and the fact that the bulk of the IPO net proceeds has already been applied to repay borrowings.
657.79 (Rs. in Million)Net Profit for the period (consolidated), half year
Net Profit for the period (consolidated), quarter517.18 (Rs. in Million)
Profit after tax, quarter140.61 (Rs. in Million)
2,799.28 (Rs. in Million)+43.2%
20251,955.15 (Rs. in Million)20262,799.28 (Rs. in Million)
Also from Symbiotec Pharmalab
Symbiotec Pharmalab Ltd press release, Q2 FY27
5 Nov 2026
Symbiotec Pharmalab Q2 FY27: revenue up 43% to Rs. 280 crore, PAT up 169% to Rs. 52 crore
5 Nov 2026
Symbiotec Pharmalab Q2 & H1FY27 earnings call on November 6, 2026, hosted by Avendus Spark
28 Oct 2026
More numbers
- Revenue from operations (consolidated), quarter ended Sep 30, 20262,799.28 (Rs. in Million)
- Revenue from operations (consolidated), quarter ended Sep 30, 20251,955.15 (Rs. in Million)
- Net Profit for the period (consolidated), quarter517.18 (Rs. in Million)
- Net Profit for the period (consolidated), half year657.79 (Rs. in Million)
- IPO issue price per equity shareRs. 988 per share
- Fresh issue aggregatingRs. 1,500.00 million
- Net IPO proceeds received by the companyRs. 1,420.25 million
- Net proceeds used for prepayment/repayment of borrowings1125.00 (Amount in Rs. millions)
- Total income, latest quarter2,800.40 (Rs. in Million)
- Total income, year-ago quarter1,956.75 (Rs. in Million)
- Total income, previous quarter2,184.88 (Rs. in Million)
- Total comprehensive income, latest quarter524.05 (Rs. in Million)
- Total comprehensive income, year-ago quarter192.78 (Rs. in Million)
- Total comprehensive income, previous quarter141.27 (Rs. in Million)
- Profit after tax, latest quarter517.18 (Rs. in Million)
- Profit after tax, year-ago quarter192.18 (Rs. in Million)
- Profit after tax, previous quarter140.61 (Rs. in Million)
- Revenue from operations, latest quarter2,799.28 (Rs. in Million)
- Revenue from operations, year-ago quarter1,955.15 (Rs. in Million)
- Revenue from operations, previous quarter2,181.50 (Rs. in Million)
- Profit before tax, latest quarter640.44 (Rs. in Million)
- Profit before tax, year-ago quarter334.70 (Rs. in Million)
- Profit before tax, previous quarter175.32 (Rs. in Million)
Source: BSE · 5 Nov 2026
Nothing here is a view, opinion or recommendation of ScoutQuest, its parent, directors or employees. ScoutQuest is a technology company: this page was assembled automatically from public sources using artificial intelligence, and may contain errors or omissions. Confirm everything against the original source before you act on it. Any use of this page is at your own risk, and neither ScoutQuest nor its parent, directors or employees accepts liability for it.